A5036344172- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Cancer Cells and Metastasis
- BRCA gene mutations in cancer
- Global Cancer Incidence and Screening
- Cancer Immunotherapy and Biomarkers
- Breast Implant and Reconstruction
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Cancer Risks and Factors
- Chronic Lymphocytic Leukemia Research
- Cancer-related Molecular Pathways
- Metastasis and carcinoma case studies
- Health Systems, Economic Evaluations, Quality of Life
- Cancer survivorship and care
- Chemotherapy-induced cardiotoxicity and mitigation
- Colorectal Cancer Treatments and Studies
MultiMedica
2020-2021
European Institute of Oncology
2009-2018
International Breast Cancer Study Group
1990-2016
Dana-Farber Cancer Institute
1989-2016
National Institute of Oncology
2016
Swiss Group For Clinical Cancer Research
2016
Ospedale regionale di Lugano
1981-2015
Ripamonti
2000-2014
University of Milan
2009-2014
Breast International Group
2014
Abstract Purpose: The purpose of this research was to identify factors predicting response preoperative chemotherapy. Experimental Design: In a large volume laboratory using standard immunohistochemical methods, we reviewed the pretreatment biopsies and histologic specimens at final surgery 399 patients with or locally advanced breast cancer (cT2-T4, N0–2, M0) who were treated incidence pathological complete remission node-negative status assessed respect initial clinical findings....
The prognostic significance of histologic tumor grade has been evaluated in 1537 women entered into the Ludwig Trials I-IV adjuvant therapy for node-positive breast cancer. Tumor was determined on review primary sections by two central pathologists using a modification Bloom and Richardson grading system. 5-year overall survival rates (±SE) were: Grade 1, 86% ± 2; 2, 70% 3, 57% 2 (P <0.0001). This difference seen both premenopausal <0.0001) postmenopausal women. Significant differences...
PURPOSE We performed a randomized phase III multicenter study to compare systemic treatment versus no after complete excision and radiotherapy for isolated first locoregional recurrence in patients with breast cancer. PATIENTS AND METHODS One hundred sixty-seven good-risk an estrogen receptor (ER+) positive or, case of unknown status, disease-free interval (DFI) greater than 12 months < or = three recurrent tumor nodules each 3 cm diameter were entered onto the study. They observation...
Eight hundred eighteen premenopausal or perimenopausal breast cancer patients with axillary node metastases were treated adjuvant chemotherapy (CMF) without endocrine treatment (prednisone, oophorectomy) in two concurrent prospective trials. Three fifty-two (43%) had recurrent disease at a median follow-up time of 6 years. The 2-year survival percentages from first relapse 16% for initial visceral multiple sites (including bone and soft tissue), 41% those regional skeletal alone 70% isolated...